Sugi Predict

Sugi Predict / Compounds / SCHEMBL264545

SCHEMBL264545

SCHEMBL264545

CC(C)C(=O)Nc1nc2c(ncn2[C@H]2C[C@H](O)[C@@H](CO)O2)c(=O)[nH]1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 1/20 0.72
▸ POLA1 P09884 1/20 0.62
▸ HIF1A Q16665 1/20 0.51
▸ TAS1R3 Q7RTX0 1/20 0.50
▸ TAS1R1 Q7RTX1 1/20 0.50
▸ PNP P00491 1/20 0.50
▸ LMNA P02545 1/20 0.50
▸ TP53 P04637 1/20 0.50
▸ HTT P42858 1/20 0.50
▸ PDE4D Q08499 1/20 0.50
▸ PDE3A Q14432 1/20 0.50
▸ SMN1; SMN2 Q16637 1/20 0.50
▸ RXFP1 Q9HBX9 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20346237 1.00 KDM4E (0.72) KDM4EPOLA1HIF1ATAS1R3TAS1R1
SCHEMBL264546 1.00 KDM4E (0.72) KDM4EPOLA1HIF1ATAS1R3TAS1R1
SCHEMBL25507075 1.00 KDM4E (0.72) KDM4EPOLA1HIF1ATAS1R3TAS1R1
SCHEMBL12714741 1.00 KDM4E (0.72) KDM4EPOLA1HIF1ATAS1R3TAS1R1
SCHEMBL10068104 1.00 KDM4E (0.72) KDM4EPOLA1HIF1ATAS1R3TAS1R1
SCHEMBL25504735 0.93 KDM4E (0.65) KDM4EPOLA1HIF1ATAS1R3TAS1R1
SCHEMBL17676619 0.93 KDM4E (0.65) KDM4EPOLA1HIF1ATAS1R3TAS1R1
SCHEMBL9340939 0.92 KDM4E (0.64) KDM4EPOLA1HIF1ATAS1R3TAS1R1
SCHEMBL6332159 0.92 KDM4E (0.64) KDM4EPOLA1HIF1ATAS1R3TAS1R1
SCHEMBL6332162 0.92 KDM4E (0.64) KDM4EPOLA1HIF1ATAS1R3TAS1R1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 175 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4606903-A1 METHOD FOR ENZYMATIC SYNTHESIS OF NUCLEOSIDE CONTAINING PROTECTING GROUP, AND COMPOSITION Asymchem Life Science (Tianjin) Co., Ltd (CN) 2025-08-27 — — EP claimed
WO-2024082545-A1 METHOD FOR ENZYMATIC SYNTHESIS OF NUCLEOSIDE CONTAINING PROTECTING GROUP, AND COMPOSITION 凯莱英生命科学技术(天津)有限公司 2024-04-25 — — WO claimed
CN-114369123-A Efficient preparation method of 5' -aminodeoxynucleoside 山东明化新材料有限公司 2022-04-19 — — CN claimed
EP-4741411-A2 OLIGONUCLEOTIDE PRODUCTION METHOD, AND NUCLEOSIDE, NUCLEOTIDE, OR OLIGONUCLEOTIDE AJINOMOTO CO., INC. (JP) 2026-05-13 — — EP disclosed
US-20260125413-A1 UNIVERSAL SOLID SUPPORTS AND PHOSPHORAMIDITE BUILDING BLOCKS FOR OLIGONUCLEOTIDE SYNTHESIS AM CHEMICALS LLC (US) 2026-05-07 — — US disclosed
US-20260117148-A1 SEMICONDUCTOR TREATMENT LIQUID, TREATMENT METHOD FOR OBJECT TO BE TREATED, AND MANUFACTURING METHOD OF ELECTRONIC DEVICE FUJIFILM CORP (JP) 2026-04-30 — — US disclosed
US-12559517-B2 Oligonucleotide manufacturing method AJINOMOTO CO., INC. (JP) 2026-02-24 — — US disclosed
US-20250320430-A1 SEMICONDUCTOR TREATMENT LIQUID, TREATMENT METHOD FOR OBJECT TO BE TREATED, AND MANUFACTURING METHOD OF ELECTRONIC DEVICE FUJIFILM CORP (JP) 2025-10-16 — — US disclosed
EP-4606903-A1 METHOD FOR ENZYMATIC SYNTHESIS OF NUCLEOSIDE CONTAINING PROTECTING GROUP, AND COMPOSITION Asymchem Life Science (Tianjin) Co., Ltd (CN) 2025-08-27 — — EP disclosed
EP-4577539-A1 UNIVERSAL SOLID SUPPORTS AND PHOSPHORAMIDITE BUILDING BLOCKS FOR OLIGONUCLEOTIDE SYNTHESIS AM Chemicals Llc (US) 2025-07-02 — — EP disclosed
WO-2025134877-A1 KIT AND METHOD FOR MANUFACTURING SEMICONDUCTOR DEVICE FUJIFILM CORPORATION (JP) 2025-06-26 — — WO disclosed
WO-1986005519-A1 POLYNUCLEOTIDE ASSAY REAGENT AND METHOD SUMMERTON JAMES 1986-09-25 — — WO disclosed
WO-1986005518-A1 STEREOREGULAR POLYNUCLEOTIDE-BINDING POLYMERS SUMMERTON JAMES 1986-09-25 — — WO disclosed
EP-0188400-A2 Oligopeptides, intermediates and process for their preparation CIBA-GEIGY AG (CH) 1986-07-23 — — EP disclosed
EP-0169787-A1 Use of oligonucleotides bonded to an intercalating agent as drugs CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) 1986-01-29 — — EP disclosed
EP-0168342-A1 Process for the preparation of thrombin inhibitors CIBA-GEIGY AG (CH) 1986-01-15 — — EP disclosed
EP-0146785-A1 Process for the preparation of protease inhibitors CIBA-GEIGY AG (CH) 1985-07-03 — — EP disclosed
US-4511713-A Process for selectively controlling unwanted expression or function of foreign nucleic acids in animal or mammalian cells THE JOHNS HOPKINS UNIVERSITY (US) 1985-04-16 — — US disclosed
US-4500707-A Nucleosides useful in the preparation of polynucleotides UNIVERSITY PATENTS, INC. (US) 1985-02-19 — — US disclosed
US-4469863-A ANTITUMOR AGENTS, VIRICIDES GENTA INCORPORATED 1984-09-04 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260117148-A1 SEMICONDUCTOR TREATMENT LIQUID, TREATMENT METHOD FOR OBJECT TO BE TREATED, AND MANUFACTURING METHOD OF ELECTRONIC DEVICE TPMT, P2RY13, TST KDM4E 3987/4885POLA1 1028/4885HIF1A 4806/4885
US-12559517-B2 Oligonucleotide manufacturing method POLL, IGF2BP1, POLI KDM4E 3231/4885POLA1 31/4885HIF1A 1827/4885
US-20260125413-A1 UNIVERSAL SOLID SUPPORTS AND PHOSPHORAMIDITE BUILDING BLOCKS FOR OLIGONUCLEOTIDE SYNTHESIS SSU72, NSUN2, POLR2H KDM4E 1515/4885POLA1 54/4885HIF1A 2344/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.